The EPS miss and rising expense base (R&D + SG&A up 55% YoY) overshadow the VEPPANU launch. Monitor the Q4 2026 VEPPANU sales trajectory and the R289 Phase 2 dose selection by year-end for the next catalyst.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 6 $39.65entry
- T+1 · 8d ago +6.05%α +3.69% · $42.05
- T+5 · 4d ago +12.13%α +9.54% · $44.46
- T+6 · todayOpen
- T+20 · in 20d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Rigel Pharmaceuticals reported Q3 2026 revenue of $80.9M (above $80.1M consensus) and GAAP EPS of $0.65 diluted (below $0.96 consensus, a miss). Net product sales grew 13% YoY to $72.3M, driven by the VEPPANU launch ($6.6M in initial sales), but net income fell to $13.2M from $27.9M a year ago due to higher R&D and commercial costs. The company narrowed its 2026 total revenue guidance to $290-$295M (excluding VEPPANU), up slightly from the prior $285-$295M range.
Key Financial Metrics
Key Facts
- Q3 2026 total revenues of $80.9M, net product sales of $72.3M (+13% YoY), contract revenues of $8.6M
- GAAP net income of $13.2M ($0.65 diluted EPS) vs $27.9M ($1.46 diluted) in Q3 2025
- VEPPANU (vepdegestrant) launched mid-August, generated $6.6M in initial net product sales
- EPS of $0.65 diluted missed consensus estimate of $0.96
- Revenue of $80.9M slightly above consensus of $80.1M
- 2026 total revenue guidance updated to ~$290-$295M (ex-VEPPANU), from prior ~$285-$295M
- Cash and short-term investments fell to $99.3M from $155.0M at year-end 2025
- R&D expense more than doubled to $18.3M from $7.4M in Q3 2025, driven by R289 and vepdegestrant programs
Financial Impact
GAAP diluted EPS of $0.65 vs consensus $0.96 (32% miss); revenue $80.9M vs $80.1M consensus (1% beat). Net income declined 53% YoY.
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| TAVALISSE net product sales | $46.0M | +3.0% |
| REZLIDHIA net product sales | $9.9M | +20.0% |
| GAVRETO net product sales | $9.8M | -11.0% |
| VEPPANU net product sales | $6.6M | Not reported |
Risk Factors
- EPS miss of 32% vs consensus may pressure the stock near-term
- Cash burn accelerated: cash dropped $55.7M from Dec 2025 to Sep 2026
- VEPPANU launch is early; sustainability of $6.6M quarterly run-rate is unproven
- R&D spending likely to remain elevated with two late-stage programs
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001034842-26-000062 |
| Document: 0001034842-26-000062-index.html | 0001034842-26-000062 |
| Document: 0001034842-26-000062.txt | 0001034842-26-000062 |
| 8-K Data (Synthetic) | 0001034842-26-000062 |
Track record
12 reports on RIGL
1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +25.02% at T+60 after the May 12, 2026 report. 2 of 3 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $45.03 Now $43.73 −2.89% settles Feb 12
- Nov 13, 20263d ago SC 13G Neutral 3/10 Entry $44.21 Now $43.73 −1.09% settles Feb 12
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $43.91 Now $43.73 −0.41% settles Feb 8
- Nov 5, 202611d ago 8-K Bearish 5/10 Viewing Entry $39.65 Now $43.73 −10.29% settles Feb 4
- Aug 4, 202614w ago 8-K Mixed 6/10 Entry $40.48 to $50.92 Now $43.73 +8.03% ▲ +25.79% +25.60% vs SPY
- Jun 17, 202621w ago 8-K Neutral 4/10 Entry $32.91 to $45.35 Now $43.73 +32.88% ▲ +37.80% +35.91% vs SPY
- Jun 11, 202622w ago Institutional Cluster Neutral 3/10 Entry $32.08 to $48.67 Now $43.73 +36.32% ▲ +51.71% +47.32% vs SPY
- May 20, 202625w ago 8-K Neutral 2/10 Entry $29.19 to $42.45 Now $43.73 +49.81% ▲ +45.43% +41.13% vs SPY
- May 12, 202626w ago 8-K Bullish 7/10 Entry $32.13 to $40.17 Now $43.73 +36.10% ▲ +25.02% +20.59% vs SPY
- May 5, 202627w ago 8-K Bearish 7/10 Entry $26.67 to $36.81 Now $43.73 −63.97% ▼ −38.02% −35.96% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers